Skip to content

Case Control study to check the effect of Measles vaccine in prevention of COVID-19

A Case Control Study to Assess Effectiveness of Measles Containing Vaccine in Preventing Coronavirus Disease (COVID-19) - MV-CCS-01

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/09/027785
Enrollment
548
Registered
2020-09-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Not applicable: Not applicable

Sponsors

Serum Institute of India Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Participants >=1years of age and 2. Participants with a known MCV status i.e. having history and documented evidence (MCH Card, School certificate of MR campaign, anganwadi/health center data) of having received a MCV. 3. Parents/guardians of participants willing to verbal consent. 4. Participants whose parents/guardians are willing to answer questions over telephone and share photos of the required documents.

Exclusion criteria

Exclusion criteria: 1. Participants with an unknown MCV status. 2. Participants who did not undergo COVID-19 testing in the defined periodi.e. between 1 February 2020 and 31 July 2020.

Design outcomes

Primary

MeasureTime frame
The proportion of vaccinated participants with a confirmed COVID-19 result (cases) and a negative COVID-19 result (control)Timepoint: Throughout the study period

Secondary

MeasureTime frame
Proportion of vaccinated participants with Laboratory Confirmed COVID-19 with severe, critical or life-threatening severity as assessed by the COVID-19 disease severity criteria listed in the COVID-19 management guidelines provided by Ministry of Health and Family Welfare (17) Timepoint: Throughout the study period

Countries

India

Contacts

Public ContactDr Prasad Kulkarni

Serum Institute of India Pvt Ltd

drpsk@seruminstitute.com020-26602384

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026